---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000130"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-10-11T23:59:59+00:00"
generated_at: "2026-05-30T15:22:42.590102+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nurix Therapeutics reports Q3 FY2024 net loss $49M, $0.67 per share; cash $457.5M

## Summary
- Net loss $49.0M ($0.67 per share) vs $37.0M ($0.68 per share) in Q3 FY2023.
- Collaboration revenue $12.6M, down from $18.5M, reflecting end of Gilead research term offset by Pfizer deal.
- Cash and marketable securities $457.5M as of Aug 31, 2024, up from $452.5M at May 31, 2024.
- NX-5948 Phase 1b expansion started in CLL, Waldenstrom's, follicular, marginal zone lymphoma; FDA Fast Track for CLL.
- NX-2127 enrollment reinitiated with new chirally controlled drug product after FDA partial clinical hold lift.

## SEC filing metadata
- accession: 0001549595-24-000130
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-10-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000130/0001549595-24-000130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000130/nrix-20241011.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000130
- JSON: https://secwatch.observer/filing/0001549595-24-000130.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.